Background: The use of psychotropic drugs, namely those with an antidepressant profile (ADs), is a mandatory part of an integrated treatment of psychiatric disorders among cancer patients. We aimed to synthetize the most relevant data emerging from published studies to provide tips about the use of ADs in oncology.
Introduction
Although emotional distress needing clinical attention can affect 40%-60% of cancer patients [1] , a formal diagnosis of a psychiatric disorder according to the usual nosology psychiatric systems, such as the International Classification of Disease of the World Health Organization or the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, can be made in about 25%-30% [2, 3] . Among these, adjustment and stress-related disorders and major depression have been most studied in terms of prevalence, consequences and treatment in oncology [4] [5] [6] [7] [8] .
Accumulated research over the last 35 years has examined the role of antidepressants (ADs) in the reduction of depressive symptoms and improvement of quality of life among cancer patients [9] [10] [11] . Two important qualifications should be noted in the research findings on AD treatment in cancer. The first is that ADs have been shown to be effective in the treatment of other psychiatric disorders, mainly stress-related disorders and anxiety disorders [12, 13] . The second is that ADs have also been used as adjuvant treatment of non-psychiatric cancer-linked symptoms, such as hot flashes, neuropathic pain, nausea and vomiting, fatigue and pruritus [14] . For these reasons, it has been suggested that these medications should be referred to in terms of their pharmacodynamic profile, which may then be linked to the underlying neurobiological characteristics of the symptoms, the neurotransmitter or molecular system being modified and the mechanism of the action, described as the Neuroscience-Based Nomenclature [15] . This can help clinicians to appreciate the pharmacologic profile of these drugs, the different therapeutic mechanisms and the effects at different doses [16] in the context of an integrated pharmacological and psychological ('PsychopharmOncology') treatment model in oncology [17] .
The aims of this narrative review are (i) to summarize the characteristics, the precautions and safety profile of ADs in the treatment of depression, other psychiatric disorders and cancer-related symptoms in cancer patients; and (ii) to suggest guidelines for an appropriate and evidence-based use of ADs in oncology.
Methods

Literature search
A search was made of the major databases from 1997 to 2017 (Embase/Medline, PsycLIT, PsycINFO and the Cochrane Library). Included studies were identified from the reference lists of previous narrative reviews, systematic reviews and metaanalyses summarizing the results from observational studies and randomized clinical trials (RCTs) related to the use of ADs drugs in oncology. When there were no reviews or meta-analyses available, we searched for primary observational studies and RCTs, including searches of the content lists of key journals to identify any additional reviews or meta-analyses missed by the electronic search. Studies published in conference proceedings, qualitative research, commentaries and discussions, letters, or in nonEnglish language journals were excluded.
Search terms
We searched the databases for articles that met the inclusion criteria using pre-specified MESH terms that included 'Cancer (EXP)' or 'Cancer' and 'antidepressants (EXP)' or 'major depression (EXP)' or 'Depressive disorders (EXP)' or 'mood disorders (EXP)' or 'demoralization (EXP)' or 'adjustment disorders with depressed mood (EXP)' or 'PTSD (EXP)' or 'Anxiety disorders (EXP) ' 
Results
After searching and screening the literature, 4 narrative reviews, 3 systematic reviews, 5 meta-analyses, 4 clinical practice guidelines and 59 clinical trials meeting the inclusion criteria were identified (supplementary Table S1 , available at Annals of Oncology online). Studies that were incomplete, not sufficiently informative or not examining the role of ADs in a comprehensive way were excluded. The topic areas relative to ADs in oncology were then divided into ADs' characteristics and their use in clinical practice, pharmacokinetics and pharmacodynamics and drug-drug interactions, precautions and side-effects, and clinical disorders (psychiatric and cancer-related syndromes) benefit of ADs.
Antidepressants characteristics and mechanisms of action
There are several different classes of ADs with different mechanisms of action. Some of these drugs, especially the first-generation ADs, such as monoamine oxidase inhibitors (MAOIs), retain a minor role in the treatment of some forms of resistant depression, but are not part of routine care in oncology. They should usually be avoided because of the high risk of potentially lethal drug interactions with other commonly prescribed medications in cancer patients (e.g. opioids). Other first-generation ADs, such as tricyclic antidepressants (TCAs), have several side-effects related to their anticholinergic profile that may be problematic for many cancer patients.
Over the last decades, new classes of ADs with less frequent and less severe adverse effects have been synthetized and marketed. These agents are mainly represented by second-generation ADs and selective ADs (the latter sometimes referred as thirdgeneration ADs). There are also recently marketed ADs (sometimes referred as fourth-generation ADs) (e.g. agomelatine and vortioxetine) for which experience in oncology settings is limited or lacking. Other drugs, such as psychostimulants and hallucinogens, have also been used and are described here according to the specific class of the medication.
Selective serotonin reuptake inhibitors. The selective serotonin reuptake inhibitors (SSRIs) are generally the first-line ADs for the treatment of depression in cancer patients, due to their tolerability. SSRIs comprise a vast class of drugs with a similar side-effect profile (e.g. gastrointestinal disturbance, headache, fatigue or insomnia, sexual dysfunction and transient increased anxiety after initiation of treatment), but there are important differences between each SSRI that may impact on treatment selection (Table 1) . Owing to its long half-life and strong cytochrome P450 (CYP450) inhibitory effects, fluoxetine should be used with caution in cancer patients receiving chemotherapy, to avoid the risk of drug interaction with anticancer agents that are metabolized through the CYP450 system. Similarly, paroxetine has prominent P450 inhibitory effects and anticholinergic effects that should be carefully monitored. Sertraline, citalopram and escitalopram have the fewest drug-drug interactions and are the best first-line treatment option. These drugs tend to be well tolerated, although caution is necessary because of the potential for QTc prolongation at higher doses and for bleeding in patients taking aspirin, nonsteroidal anti-inflammatory drugs, warfarin or heparin, because of the antiplatelet effects of SSRIs.
Selective norepinephrine reuptake inhibitors. Reboxetine and teniloxazine (the latter marketed only in Japan) are selective norepinephrine reuptake inhibitors (NRIs) used for the treatment of depression. Reboxetine has been reported to be effective in the treatment of depressed cancer patients [18] , but its efficacy has been questioned; more research in cancer patients is needed [19] .
Serotonin norepinephrine reuptake inhibitors. Venlafaxine, desvenlafaxine, duloxetine and milnacipran are drugs acting both on the noradrenergic and the serotonergic systems (dual-acting ADs). Venlafaxine works as an SSRI at lower doses and becomes a dual-acting serotonin norepinephrine reuptake inhibitor (SNRI) at doses of 150 mg and above. Desvenlafaxine is the active metabolite of venlafaxine, but has a lesser potential for drug-drug interactions because it is not metabolized by the CYP450 system. Duloxetine is an SNRI at all therapeutic doses (60-120 mg pro die). Dose-dependent hypertension may occur in patients taking venlafaxine at high doses and hepatotoxicity has been described as a rare complication of high dose duloxetine. Milnacipran was originally developed for the treatment of fibromyalgia, but has been shown to be as effective as SSRIs and other SNRIs in the treatment of depression, with similar side-effects (Table 1 ) [20] . Norepinephrine dopamine reuptake inhibitors. Bupropion is a dual-acting (i.e. noradrenergic and dopaminergic) AD, with activating properties that has been shown to help in improving fatigue and concentration in cancer patients. It tends to be weight-neutral (or, in some cases, to be associated with weight loss) and is not associated with sexual dysfunction. It should be used with caution and not as a first-line treatment option in depressed cancer patients who are cachectic, and should be avoided in depressed patients with significant anxiety, since it may increase agitation, and in patients with seizure disorders, intracranial tumours, eating disorders or alcohol withdrawal, since it decreases the seizure threshold when daily doses exceed 450 mg.
Noradrenergic and specific serotonergic antidepressants. The histaminic receptor agonism and antagonism of 5HT2 and 5HT3 receptors (noradrenergic and specific serotonergic antidepressants) gives mirtazapine anti-anxiety, sleep-inducing, antiemetic and appetite stimulating effects in addition to its antidepressant effect. Side-effects are reported in Table 1 .
Serotonin antagonist and reuptake inhibitors. The serotonin antagonist and reuptake inhibitors (SARIs) trazodone and nefazodone have both an antidepressant and anxiolytic profile.
Because it is not habit-forming, trazodone is widely used in the treatment of sleep disorders and in the palliation of symptoms in advanced phases of cancer. Orthostatic hypotension is a potential complication of the SARIs, causing dizziness and an increased risk of falling, particularly in elderly or fragile patients. Priapism is also a possible rare effect, although there are no other sideeffects on sexual function. Nefazodone has significant side-effects (including liver failure in 1 per 250 000 patient-years) and therefore should be used with caution.
Serotonin modulators and stimulators. Vilazodone and vortioxetine act as SSRIs, but also agonize and antagonize various other serotonin receptors [21] . Vilazodone has partial presynaptic agonism of 5-HT1A, which may give it more anxiolytic properties. Vortioxetine has a novel multimodal mechanism of action which is thought to help restore cognitive deficits associated with depression [22] . However, studies on the use of these newer ADs in oncology are lacking.
Melatonin agonists. Agomelatine has an agonist effect on melatonin M1/M2 receptors and an antagonist action on serotonin (5-HT2C) receptors [23] , with a positive effect on sleep and lack of sexual side-effects seen with other ADs. It is contraindicated in patients with renal or hepatic impairment and, because of the possibility of an increase in the levels of liver enzymes, monitoring of liver activity is recommended at the initiation of the treatment and periodically during treatment. Studies on the use of agomelatine in oncology are lacking.
Other drugs. Traditional psychostimulants (methylphenidate and dexamphetamine), which show sympathomimetic properties, have been proposed for the treatment of depression in cancer [24, 25] . The effect of psychostimulants in promoting wakefulness and in elevating mood, with a rapid onset of action of hours to days rather than weeks, would be beneficial in patients with advanced disease. There is some evidence to support their use in the treatment of anorexia, impaired attention and concentration, opiate-induced sedation and pain [26, 27] , at low doses that avoid side-effects (Table 1 ) [28] . However, evidence of their efficacy in the treatment of depression is not clear [29] , with some positive results in some studies [30] , but not in others [31] . Because of their sympathomimetic effects, caution is advised in patients with hypertension or arrhythmias. Stimulant-like drugs (e.g. modafinil and armodafinil), which affect histamine projections to the hypothalamus and act as agonists of the noradrenaline receptors, have been proposed for their wakefulness-promoting action in patients with cancer. They seem to lack the tolerance or dependence effects seen with other stimulants but also lack their euphoric effects; data from cancer patients are lacking.
Ketamine is an N-methyl-D-aspartate receptor antagonist that has been for a long time used as an anaesthetic agent. Its antidepressant effects and properties have been recently tested, with a rapid effect (one day) observed, although its use is currently reserved for severe and treatment-resistant depression [32] . A few non-controlled studies are available on the rapid response to ketamine in advanced cancer patients [33, 34] for acute depressive symptoms and suicidal ideation in newly diagnosed cancer patients [35] . More data should be collected, however, to establish guidelines for practice and to monitor the potential risk of ketamine treatment [36] .
Psilocybin is similarly an old drug repurposed for use to rapidly alleviate depression in cancer patients, particularly related to end-of-life distress [37] , although studies are just beginning to emerge.
Drugs that act not only on the monoaminergic system (as the SSRI, NRI, SNRI) but also on other molecular mechanisms, including glutamatergic neurotransmission, may have future significant applications in cancer and other medically ill patients [38, 39] .
Pharmacokinetics, pharmacodynamics and potential drug-drug interactions
Information about pharmacokinetics/pharmacodynamics of psychotropic drugs and the main drug-drug interaction in oncology is extremely important, since polypharmacy is common in cancer patients [40, 41] . Most ADs are metabolized through the CYP450 enzyme system and drug-drug interaction is linked to the level of inhibition of CYP450 isoenzymes. Drug interactions between ADs and chemotherapeutic agents may compromise the effectiveness of chemotherapy or increase toxicity of treatment, adversely affecting well-being and survival. However, by virtue of their more selective mechanism of action and receptor profile, newer ADs have a relatively low risk for pharmacodynamic drug interactions, compared with the first-generation ADs (i.e. TCAs and MAOIs). However, the concomitant use of antiepileptics, antimycotics, antibiotics, chemotherapeutic agents and other drugs that cancer patients take and the effect of CYPD26 inhibiting ADs should be carefully monitored [42] .
A specific interaction has been reported with the use of SSRIs/ SNRIs in breast cancer patients receiving selective estrogen receptor modulators (SERM), such as tamoxifen. Data have accumulated showing that paroxetine, fluoxetine, venlafaxine and bupropion have significant CYP2D6-inhibiting properties [43] [44] [45] , which may decrease the plasma concentration of endoxifen (the active metabolite of tamoxifen via CYP2D6) [46] . The consequence in terms of survival of cancer patients is, however, still controversial. Some data indicate a higher risk of recurrence of breast cancer in patients receiving tamoxifen and CYP2D6-inhibiting drugs [47] [48] [49] , whereas more recent data have not shown such an effect [50, 51] . The International Tamoxifen Pharmacogenomics Consortium has underlined the need for more prospective data on this interaction, controlling for all the possible variables (e.g. type of major alleles of CYP2D6 conferring a decreased CYP2D6 activity, polymorphisms and menopausal state) influencing the metabolic activity [52] . Recommendations have been dispensed to avoid or use with caution ADs with stronger CYPD26-inhibiting action (e.g. paroxetine) in patients on tamoxifen (particularly those with allelic variants of CYP2D6 exposing them to be poor metabolizers) [53, 54] . Also, switching cancer patients receiving paroxetine to weaker CYP2D6-inhibiting ADs (e.g. escitalopram or venlafaxine) has been recommended [55, 56] .
Other interactions deserving attention are reported in supple mentary Table S2 , available at Annals of Oncology online.
Other side-effects
Other precautions and side-effects are summarized in Table 1,  and in supplementary Table S3 , available at Annals of Oncology online, including the risk of serotonin syndrome, a potentially life-threatening condition related to drug combinations which alone or combined synergistically increase serotonin to toxic levels. Potential consequences of this include operative bleeding risk during and immediately after surgery, due to the antiplatelet activity of serotonin; discontinuation or SSRI withdrawal syndrome; and a rare (1/1000 to 1/10 000) drug rash with eosinophilia and systemic symptoms, which is a severe cutaneous eruption that has been linked to several common drugs and drug categories, including psychotropic drugs.
Clinical contexts of ADs use
Psychiatric disorders.
Depression: Depressive disorders must be carefully differentiated from normal sadness and physiological depressive conditions [6] , but their prevalence in cancer patients appears to be two to three times than in the general population [3, 57] . A systematic review and meta-analysis [58] showed that, irrespective of their class, ADs are more effective than placebo in treating depression among cancer patients. However, ADs should generally be reserved for more severe presentations of depression and always be integrated with psychological therapies, which are the first line of treatment in mild to moderate forms of depression [59] .
Stress-related disorders: Stress and stress-related disorders, including acute stress disorders, post-traumatic stress disorders (PTSD) and adjustment disorders are also common and distressing syndromes in cancer patients [60] . Meta-analyses and reviews of the several studies conducted in the area indicate a 12%-25% prevalence of PTSD among cancer patients [61, 62] . The clinical literature on the efficacy of ADs for the treatment of PTSD underlines SSRIs as the preferred initial class of medications [63] , although there are no specific treatment outcome data in cancer settings. Adjustment disorders occur in up to 20% of cancer patients [3] , where there has been only very limited evidence of benefit of ADs.
Anxiety disorders: For anxiety disorders (e.g. phobias; severe and persistent anticipatory fears, including chemotherapyinduced anticipatory nausea and vomiting; social anxiety, etc.), SSRIs, SNRIs and mirtazapine are the drugs of choice in cancer patients, sometimes together with benzodiazepines [64] .
Sleep disorders: Sleep/wake cycle dysregulation, as part of depressive, stress-related and anxiety disorders or as complications of medical procedures, is common in cancer patients and should be properly addressed [65] . In addition to the use of hypnotics, mostly benzodiazepines, ADs with sedative components (e.g. mirtazapine and trazodone) may be useful.
Cancer-related symptoms/syndromes
Clinical practice, supported by scientific evidence, has shown that ADs can be used to improve non-psychiatric cancer-related symptoms, such as loss of appetite, sleep disturbances, pain, anxiety and fatigue, which remarkably interfere with quality of life.
Pain. Pain is one of the most disabling conditions in cancer patients. The efficacy of ADs, as a supplement to the primary analgesics, has been underlined by several reviews [66] [67] [68] . The use of ADs as a co-adjuvant treatment in cancer pain has also been recommended in the European Society of Medical Oncology (ESMO) Guidelines for cancer pain management [69] . Among the several classes, the old TCAs and more recently SNRIs (venlafaxine and duloxetine) have been suggested to be effective in the treatment of neuropathic pain in cancer patients on chemotherapy [70, 71] . However, a recent meta-analysis [72] has underscored the heterogeneity of patient samples in the available studies and the importance of balancing the likelihood of benefit against the risk of adverse effects of ADs combined with opioid or antiepileptic drugs for cancer pain.
Hot flashes. Hot flashes secondary to the use of SERM or aromatase inhibitors may cause negative affect, fatigue, sleep difficulties and overall poor quality of life [73] . ADs, especially SSRIs and SNRIs, have been shown to be effective in treating hot flashes, although caution is required in use of SSRIs and SNRIs for hot flashes because of the potential for CYP2D6 inhibiting effects.
Appetite and nausea/vomiting. The anti-histaminergic properties of mirtazapine have shown it to be useful in counteracting nausea, chemotherapy-induced anorexia/cachexia and severe weight loss [74] . A phase II trial confirmed its beneficial impact on appetite, sleep disturbances, anxiety, pain and quality of life, as well as depression in cancer patients [75] .
Fatigue. Fatigue is also a common symptom in cancer patients, with studies investigating the possible adjuvant benefit of psychotropic drugs [76] . The antidepressant norepinephrine dopamine reuptake inhibitor bupropion has been suggested to reduce cancer-related fatigue [77] , based on dopaminergic activity.
Among psychostimulants, methylphenidate [78] and modafinil have also been considered [79] , with some contrasting results [80, 81] and further research needed [82] .
Guidelines for the use of ADs in cancer care
Based on the recommendations of scientific bodies for the treatment of AD in psychiatric and primary care populations [83] [84] [85] [86] [87] , several guidelines have been developed for oncology [88] [89] [90] [91] [92] and palliative care [93] . The most significant steps, general rules and caveats when prescribing ADs in cancer care and treating cancer patients are summarized in Table 2 . Table 3 provides practical guidance on the most commonly used first-line ADs for treating major depression in cancer patients, based on extrapolation from practice in other medical populations [94] . Level of evidence in cancer populations is provided based on CANMAT criteria [11] , with the strength of the recommendation based on Grade Levels [95] .
Discussion
ADs have been shown to be effective in the treatment of cancer patients with more severe major depression and in those with other cancer-related distressing symptoms [58, 96] . The efficacy of ADs is positively associated with length of treatment, and no difference has been reported between ADs and placebo in terms of overall acceptability [97, 98] . There are, however, limitations and general cautions to be taken into consideration.
It should be underscored that that there is still a debate ongoing about the effect of ADs in the treatment of both major depression and persistent forms of depression, with some data suggesting an overestimation of the effect of ADs due to selective publishing and selection of patients who have a high likelihood of response in RCTs. More sound methodological studies are needed to clarify the benefit compared with placebo, since many reported studies of ADs have been too small to prove clinical relevance [99, 100] . In the specific setting of oncology, the paucity of data and the limited volume and methodology of reported RCTs have been noted as problems to be resolved in future studies [101] . More specific data are also needed regarding follow-up response (>12 weeks) and dropouts. Current evidence is based on studies with small sample sizes and wide confidence intervals, and inconsistency due to statistical or clinical heterogeneity. Larger RCTs comparing commonly used ADs to placebo (or other ADs) in people with cancer and depressive disorders are urgently needed to better inform clinical practice [102] [103] [104] . This is even more necessary with regard to the psychopharmacological treatment of other psychiatric disorders, such as PTSD, or anxiety disorders in cancer patients [62, 105] .
More information is also needed about the way in which cancer care professionals use ADs. Recent research has confirmed a gradual increase in the rate of AD prescription, with the intent of addressing the symptoms of depression [106, 107] , among cancer patients, including long survivors [108] . A recent review indicates that the prescribing patterns of ADs in oncology is related to several patient variables, including gender (females > men), ethnicity (Caucasians receiving more SSRIs than other ethnic groups) Table 2 . Practical tips in the use of ADs in cancer patients
Practical tips
• Start the treatment at low doses followed by a period of dose titration to achieve an optimum individualized response (low doses may help to avoid unwanted initial side-effects, particularly in patients in poor physical conditions) • Consider to use ADs according to their profile: for patients with anxiety symptoms or sleep disorder, use ADs with a sedative profile; for patients with low energy or psychomotor retardation, use ADs with an activating profile (see Table 1 ) • Inform and reassure patients of latency period (beneficial effects usually start within 2-4 weeks of their initiation, with the full effect in about 4-6 weeks) and possible side-effects, in order to avoid premature dropout, especially if patients are receiving other medications • Treat the patient for 4-6 months in order to avoid relapses or recurrence of episodes after remission. Treat the patients for longer periods, if previous major depressive episodes were present (major recurrent depression) • Regularly monitor the patient's physical variables and concomitant use of medications for cancer (e.g. steroids, antiemetics, antibiotics, antiestrogen and chemotherapy agents) • Discontinue medications by tapering the dose by 50% over a couple of weeks to reduce the risk of withdrawal symptoms that can be distressing and may be mistaken for symptoms of cancer illness or relapse into depression • Patients at higher risk of suicidality should be prescribed a limited quantity of antidepressant medications and monitored in follow-up more frequently
Factors to be considered when prescribing ADs in cancer
• Past psychiatric history (e.g. assess for past positive treatment responses to an antidepressant)
• Concurrent medications (e.g. assess for potential drug-drug interactions)
• Somatic symptom profile (e.g. a sedating antidepressant may be preferable for those with prominent insomnia; cachectic patients may benefit from antidepressants that stimulate weight gain) • Potential for dual benefit (e.g. duloxetine for neuropathic pain, venlafaxine for hot flashes)
• Type of cancer (e.g. avoid bupropion in those with central nervous system cancers due to elevated seizure risk)
• Co-morbidities (e.g. avoid psychostimulants or tricyclic antidepressants in those with symptomatic cardiac disease)
• Cancer prognosis (e.g. in setting of terminal disease, the rapid onset of action of psychostimulants/ketamine may be preferable) and treatment (more in patients with extensive cancer treatment) [109, 110] , with only few studies reporting data on exact dose or follow-up regimens [111] . However, the need for correct assessment and diagnosis of depression and other psychopathological conditions is extremely important. A large number of cancer patients suffer from emotional distress not requiring AD treatment (e.g. mild-moderate distress, adjustment disorders with depressed mood, etc.), while a minority can be diagnosed with severe forms of depression needing AD treatment. A more integrated liaison between psychiatry and oncology is needed to address this overuse, as well as the opposite problem of undertreatment of depressed cancer patients who would benefit from ADs. Walker et al. [112] showed, for example, that of 1538 patients diagnosed with major depression, 1130 (73%) were not receiving effective AD treatment, while Fisch et al. [113] found that among 3106 cancer patients, only one-fourth of those with clinically significant depression were properly treated. The continuous, coordinated and comprehensive role of primary care for cancer patients and their families may also help in this regard at all stages of cancer [114] .
A third related issue is the need for collaborative care integrating psychopharmacology and psychosocial intervention. In general clinical psychiatry, this has been shown to be more effective than single interventions in both depressive and anxiety disorders [101, 115] . Evidence also indicates that a sequential integration of psychotherapy and pharmacotherapy is a viable strategy for preventing relapse and recurrence in severe forms of depression (e.g. major depression) and that discontinuation of ADs may be feasible when psychotherapy is provided [116] . In oncology, there is a marked need for the integration of pharmacological and psychosocial intervention [117] . This is important because psychosocial intervention is the treatment of choice for mild and moderate forms of depression and because collaborative care treatment programmes are cost-effective for cancer patients with elevated symptoms of depression [118] . They have been associated with improvement of psychological and somatic symptoms, health, and quality of life compared with usual care. A collaborative care model that incorporates a stepped care approach by integrating pharmacologic, psychological and practical management [59] can improve the effectiveness of the treatment of psychosocial disorders in patients with cancer [119] and can maximize the treatment outcome of depression [98, 120] .
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